Apraglutide is under clinical development by VectivBio and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Apraglutide’s likelihood of approval (LoA) and phase transition for Short Bowel Syndrome took place on 19 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Apraglutide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Apraglutide overview

Apraglutide (FE-203799) is under development for the treatment of short bowel syndrome intestinal failure (SBS-IF) and gastrointestinal acute graft versus host disease (GVHD). It is administered through subcutaneous route as a powder and solution for solution for injection. The drug candidate is a long acting synthetic peptide analogue of glucagon-like-peptide-2 (GLP-2) which acts on GLP-2 receptor. It is developed by using peptide technology. It was under development for the treatment of chemotherapy-induced gastro-intestinal mucositis.

VectivBio overview

VectivBio is biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for for severe rare conditions with high unmet medical need. The company’s lead product candidate GLP-2, targeting short bowel syndrome. VectivBio is headquartered in Basel, Switzerland.

Quick View Apraglutide LOA Data

Report Segments
  • Innovator
Drug Name
  • Apraglutide
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Immunology
  • Toxicology
Key Developers
  • Sponsor Company: VectivBio
  • Originator: Ferring International Center
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.